Topics

Articles

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

Noom to Sell Microdoses of Wegovy

The partnership is centered around cutting cold chain costs and emissions with smart packaging and carbon-neutral same-day delivery.

Invensify, Go2 Delivery Collaborate on Temperature-Controlled Courier Service

Videos

In the second part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, outlines strategies that companies can adopt to help mitigate these increasing costs.

How to Manage Rising Drug Development Costs

In the first part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, shares the key factors that he believes are propelling a continued rise in projected R&D ROI.  

The Positive Momentum Behind Pharma Innovation

Andrew Witty resigns due to personal reasons, as Stephen Hemsley, chairman and former chief executive, will assume the position.

UnitedHealth Group CEO Departs

The financial decision is due to customer demand stemming from the reshoring of drug supply services.

Piramal Pharma to Invest $90 Million in US Site Expansions

The President plans to sign an executive order on Monday morning to enforce the trade clause.

President Trump Announces Most-Favored-Nation Policy for Pharma Prices

Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.

Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market. 

Asembia 2025: A General Landscape of the Pharmaceutical Industry

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes the uneasiness behind regulatory complications. 

Business and Finance